CAJ | 학술논문

随着新的化疗药物的应用及相关临床研究的开展,胃癌围手术期化疗研究取得了一定的进步.但是姑息化疗进步甚微,晚期胃癌患者的中位生存期仍徘徊在8～10个月.随着人们对胃癌生物学行为及信号传导通路认知的深入.越来越多的靶向药物如曲妥珠单抗、贝伐珠单抗或西妥昔单抗等开始应用于临床.但同时,胃癌的高度异质性致使临床实践中出现很多困难,如怎样合理地实施围手术期化疗、如何实现细胞毒药物和靶向药物在晚期胃癌中的个体化治疗等,应密切结合我国胃癌的具体情况.开展多中心、随机和前瞻性临床研究,充分认识胃癌的异质性,深入了解其生物学特性,加强转化性研究及多学科协作,真正实现个体化治疗.
수착신적화료약물적응용급상관림상연구적개전,위암위수술기화료연구취득료일정적진보.단시고식화료진보심미,만기위암환자적중위생존기잉배회재8～10개월.수착인문대위암생물학행위급신호전도통로인지적심입.월래월다적파향약물여곡타주단항、패벌주단항혹서타석단항등개시응용우림상.단동시,위암적고도이질성치사림상실천중출현흔다곤난,여즘양합리지실시위수술기화료、여하실현세포독약물화파향약물재만기위암중적개체화치료등,응밀절결합아국위암적구체정황.개전다중심、수궤화전첨성림상연구,충분인식위암적이질성,심입료해기생물학특성,가강전화성연구급다학과협작,진정실현개체화치료.
Perioperative chemotherapy for gastric cancer has made steady progress with the application of chemotherapeutic agents and conduct of relevant clinical trials.However,palliative chemotherapy has only made marginal progress, and the median survival remains between 8-10 months,An emerging understanding of tumor biology,cellular and molecular mechanisms has revealed novel targets in gastric cancer therapy,such as trastuzumab,bevacizumab,cetuximab,etc.There are still some problems in clinical practice due to the high heterogeneity of gastric cancer including optimization of perioperative chemotherapy regimen,determination of right strategy to personalize chemotherapy or target therapy for advanced gastric cancer. In order to practically achieve individualized therapy,multicenter,prospective,randomized clinical trials according specific matters of gastric cancer should be performed in China.A deeper understanding of the biological characteristics of gastric cancer,and more translational medicine research and multi-disciplinary team collaboration should be carded out to achieve personalized medicine.